These findings suggest the key role of phospho-p70S6K1 overexpression in TNBC progression under T2DM conditions, which was further explored in vitro by targeting p70S6K1 using siRNA transfection technology and the specific pharmacological inhibitor. Here, RPS6KB1 is linked to type 2 diabetes mellitus.